DETAILED ACTION
Applicant’s arguments filed July 30, 2026 have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.
Status of Claims
Claims 4, 5, and 20 are canceled.
Claims 1-3, 6-19, and 21-23 are pending and under examination.
Information Disclosure Statement
The information disclosure statement filed November 27, 2023 fails to comply with 37 CFR 1.98(a)(3)(i) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each reference listed that is not in the English language. In this instance, while foreign document number CN115038441A has an associated section in English, this section is a duplicate of the statement of relevance for foreign document number CN112147117A and accordingly reads as a partial translation of foreign document number CN112147117A. Thus, this English section is not relevant to foreign document number CN115038441A and is not considered to be an appropriate concise explanation of relevance. The IDS has been placed in the application file, and references other than CN115038441A (which has been struck through) have been considered.
The examiner notes that Applicant’s response filed July 30, 2026 states on page 9 that a supplemental IDS with a correct translation for CN115038441A was submitted. However, no such IDS submission is present and accessible to the examiner at the time of the preparation of this office action.
Claim Interpretation
The examiner interprets the chemical formula for the manganese-based organic framework in claims 1 and 16, Mn2(TCPE)(H2O), to provide the accurate descriptive stoichiometry and compositional description of the claimed framework. In the absence of any compositional data to support stoichiometric ratios of individual components or the full elemental makeup, the provided formula is the only source of such information. Thus, it is understood that for every molecule of TCPE in the composition, there are two manganese ions and one water molecule. Furthermore, given the provided formula, it is understood that the water is coordinated to the manganese ion in the framework and is thus an integrated component of the lattice structure and not a guest molecule. If water was a guest molecule, the proper notation in the art would be [Mn2(TCPE)]·(H2O).
In claim 6, the phrase “for delivery, treatment, and/or diagnosis” is interpreted to be functional language. A composition is defined by its structure and not its intended use. Therefore, art that reads on the manganese-based organic framework being incorporated into the aforementioned devices such that it will come in contact with an object through the device reads on this claim regardless of the intended use of that art.
Claim 8 is interpreted to contain functional language. In claim 8, the phrase “for deprotonation” provides a desired function of the one or more base and does not recite a required procedural element of the claimed method.
In claim 10, “a content of dimethylformamide in the ligand solution does not exceed one quarter by volume of the ligand solution” is interpreted to mean that the ratio of the volume of dimethylformamide to the total volume of the ligand solution is less than or equal to 1/4. This is equivalent to a 1/4 v/v ratio. In other words, “a content of dimethylformamide” in the context of the phrase “by volume” is interpreted to refer to the volume of dimethylformamide in the solution.
In claim 19, step 2, the recitation of “different dialysis membranes” is interpreted to mean that the drug-loaded drug delivery material containing solution is separately injected into multiple distinct dialysis membranes.
In claim 19, step 3 describes immersing the membranes into containers containing solutions with different pH values. It is interpreted that “different pH values” refers to the pH value of the solutions into which the membranes are being immersed rather than a comparison of the pH value of the contents of the membranes and the solutions into which they will be immersed.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2, 3, 9, 19, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 2 is drawn to a tetracycline-loaded manganese-based organic framework nanocarrier. Claim 2 further recites a limitation that the manganese-based organic framework is of a size from 50 nm to 20 µm. The examiner notes that in the art of nanoparticles and metal organic frameworks, the prefix nano refers to objects of sizes measured using the nanometer unit. This tends to refer to objects between 1 nm and 100 nm, but other values less than 999 nm are sometimes included in a broader use of this prefix. Given this, the skilled artisan would interpret a nanocarrier to be a material measured using the nanometer unit. However, the size range of claim to goes up to 20 µm, which the skilled artisan would not use nanometers to describe. Therefore, the claim is indefinite because it is unclear if the manganese-based organic framework is required to have a size measured in nanometers (as implied by being a nanocarrier) or if the metal organic framework can be of sizes measured in microns. For the purpose of examination, as claim 1 (upon which claim 2 depends) requires the manganese-based organic framework be a nanocarrier, the examiner will interpret the size to be measured in nanometers and not include micron values.
Claim 3 recites the limitation "nanoparticles" in line three. There is insufficient antecedent basis for this limitation in the claim. It is unclear whether “nanoparticles” refer to the manganese-based organic framework or an additional material. This also renders the term “aggregates” at the end of the claim indefinite, as it is not clear if the drug is loaded between aggregates of manganese-based organic framework or aggregates of a separate nanoparticle. For the purpose of examination of this claim, “nanoparticles” is interpreted to refer to the manganese-based organic framework and “aggregates” is thus interpreted to mean aggregates of the manganese-based organic framework.
Regarding claim 9, the limitation “wherein a ratio of the one or more bases used for deprotonation to the ligand solution is in a range of 1:2 to 1:4” is unclear in meaning and therefore renders the claim indefinite. It is not understood what feature of these solutions is described by the provided range of ratios or what values are to be used to calculate the ratio. For example, it is unclear whether the ratio is of volume of base to volume of ligand solution, weight of base to weight of ligand solution, weight of base to volume of ligand solution, or moles of base to moles of ligand solution (the examiner notes that further options of the values used for such a ratio are possible). For the purpose of examination, this will be interpreted to describe a volume to volume ratio between the solution comprising the base required by claim 8 to the solution comprising the TCPE ligand.
Regarding claim 19, it is unclear what is meant by “keeping the containers at a constant speed on a shaker.” There appears to be a verb missing between “containers” and “at.” Thus, the claim is considered by the examiner to be indefinite or failing to particularly point out the invention. For the purpose of examination, the claim is interpreted to mean that containers are placed on a shaker and the containers and shaken at a constant speed.
Claim 21 recites that the manganese-based organic framework comprises CCH-2. However, the examiner notes that CCH-2 is not a term of the art and is not clearly sufficiently defined in the instant specification to establish defined bounds to the claim. It appears in the paragraph spanning pages 8 and 9 of the instant specification that Applicant defines CCH-2 as the product of an experimental group during the synthesis of an embodiment of the instantly claimed manganese-based organic framework. While some properties of CCH-2 are described through characterization techniques in the paragraphs following this, the structure of CCH-2 is not adequately defined in the specification such that the skilled artisan would be able to ascertain the bounds of the claim. Therefore, claim 21 is rendered indefinite.
Allowable Subject Matter
Claims 1, 6-8, 10-18, and 22-23 are allowed.
Claims 2, 3, 9, 19, and 21 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.
The examiner has cited prior art below that is relevant to the claimed invention, but over which no rejection has been written. The examiner has explained why no rejection has been written over the below-indicated prior art.
Sun Reference: As relevant prior art, the examiner cites Sun (Sun, F. Z.; et al., ACS Appl. Mater. Interfaces, 2020). Sun teaches a manganese-based organic framework of formula Mn2(TCPE)(H2O)(DMF) (pg. 6106, last paragraph). The formula provides the stoichiometric ratios of the components of the composition: for every molecule of TCPE, there are two manganese ions, one manganese-coordinated water, and one manganese-coordinated DMF. Sun teaches that the Mn2(TCPE)(H2O)(DMF) MOF has channels of a size of 4.7 x 7.8 Å2 (pg. 6107, left column, first paragraph).
Wen Reference: As relevant prior art, the examiner cites Wen (Wen, L.; et al., Chem. Commun., 2012). Wen teaches a method of single-crystal to single-crystal transformations in metal-organic frameworks in which metal coordinating DMF molecules are replaced by water molecules (pg. 2846, Abstract). Wen teaches that this conversion was done by incubating the DMF-coordinating MOF in dichloromethane for 8 hours at room temperature (pg. 2846, last paragraph). Wen further teaches that this single-crystal to single-crystal transformation resulted in increased nitrogen and hydrogen gas adsorption properties (pg. 2848, Fig. 3) and increased framework stability and surface area (pg. 2848, second paragraph).
Zhou Reference: As relevant prior art, the examiner cites Zhou (Zhou, C. C.; et al., Dalton Trans., 2021). Zhou teaches a method of single-crystal to single-crystal transformations in a manganese-containing metal-organic framework. After creating a manganese-containing MOF in which seven water molecules were coordinated for every three manganese ions, further heating and extending the reaction time enabled the removal of coordinated water molecules, generating species with six or two water molecules for every three manganese ions (pg. 11084, Fig. 5). Zhou teaches that reducing the number of manganese-coordinated water molecules increases MOF thermal stability (pg. 11084, Fig. 7) and enables tailoring interlayer distance and porosity (pg. 11084, first paragraph).
As described in the prior office action, it would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to modify the manganese-based organic framework of Sun, Mn2(TCPE)(H2O)(DMF), by incorporating the teachings of Wen (to swap the manganese-coordinated DMF with water) and Zhou (to reduce the number of coordinated water molecules), as such transformations could tailor the framework’s ability to adsorb gases, alter its porosity, and improve its stability. This would result in the predictable stepwise conversion of Mn2(TCPE)(H2O)(DMF) to Mn2(TCPE)(H2O)2 to Mn2(TCPE)(H2O), resulting in the claimed framework formula in its non-loaded form.
However, the combination of these references does not teach loading the manganese-based organic framework with tetracycline. Nor do these references teach fluorescence and pH-responsive tetracycline release properties. These references also do not teach a method of making a tetracycline-loaded manganese-based organic framework nor a method of using such a framework for drug delivery.
Zhang Reference: As relevant prior art, the examiner cites Zhang (Zhang, Y; et al., Inorg. Chim. Acta, 2018). Zhang teaches using a (Me2NH2)4Zn2(FDC)4 metal-organic framework as a drug delivery material (pg. 8, Title). Zhang teaches that the MOF contains channels of dimensions 7.2 x 7.2 Å2 (Section 3.4). Zhang further teaches that 5-fluorouracil has a molecular size of 5.3 x 5.0 Å2 (Section 3.4). In this method, the MOF is loaded with the drug 5-FU, and the drug release process comprises transferring the drug-loaded MOF to dialysis bags, placing the filled dialysis bags in phosphate buffer solutions with different pH values, and shaking the containers at 60 rpm and with the temperature set to 37°C (pg. 9-10, Section 2.6).
The examiner notes that while Zhang does teach using a MOF as a drug delivery material, Zhang teaches materially different MOF structure and drug identity. Zhang does not teach a manganese-based organic framework containing TCPE nor tetracycline loading of a MOF. The teaching of Zhang is pertinent as it relates to the predictability of tetracycline loading in the MOF of the combination of Sun, Wen, and Zhou. Zhang teaches that 5-fluorouracil has a molecular size of 5.3 x 5.0 Å2 (Section 3.4). The examiner notes that tetracycline is a larger molecule than 5-fluorouracil, containing 4 fused rings rather than a singular ring. Furthermore, as described above, Sun teaches that the Mn2(TCPE)(H2O)(DMF) MOF has channels of a size of 4.7 x 7.8 Å2 (pg. 6107, left column, first paragraph). The examiner notes that, in view of Zhang, this channel size included a dimension smaller than the size of 5-fluorouracil. Furthermore, while Zhou indicates that altering the ratio of manganese to water in the MOF lattice can modulate the pore size, Zhou specifically teaches removing water from the coordination system (as is required in the above described modification to achieve the instantly claimed MOF structure) reduces that channel size (pg. 11081, left column, second paragraph; and pg. 11082, left column, first paragraph). Thus, the skilled artisan would predict the channel size in the modified version of the MOF of Sun to have a smaller pore size than the original MOF of Sun (to the extent that such a change is predictable in view of Sun, Wen, and Zhou). In view of these teachings, the skilled artisan would not predict that tetracycline, a molecule larger than 5-fluorouracil, could effectively be loaded in the modified version of the MOF of Sun.
Taherzade Reference: As relevant prior art, the examiner cites Taherzade (Taherzade, S. D.; et al., Nanomaterials, 2017). Taherzade teaches the use of MIL-100 MOF material as a material for drug delivery (pg. 1, Abstract). More specifically, Taherzade teaches encapsulating tetracycline and doxycycline in the MIL-100 MOF nanocarrier (pg. 12, paragraph 3). Taherzade also teaches measuring drug release (pg. 11, Figure 11) by measuring the absorbance of the drug molecules (pg. 12, paragraphs 5-6). Taherzade teaches that the MIL-100 MOF was selected because it is particularly compatible with tetracycline loading as the MOF pore size is 1.2 or 1.7 nm and the molecular size of tetracycline is 1.1 nm (pg. 2, paragraph 4).
While the teachings of Taherzade suggest loading tetracycline in a MOF. Taherzade specifically teaches this in the context of the MIL-100 MOF and even suggests that MOF selection matters, specifically pointing to selecting a desired pore size for drug encapsulation. This indicates that not all MOF materials are suitable for tetracycline loading. Taherzade does not teach MOF materials comprising manganese and TCPE.
To the extent that Taherzade teaches loading tetracycline in a MOF and may provide a motivation to load another MOF with tetracycline to enable utilization of the MOF for drug loading and release, in view of the above cited references, the skilled artisan would not have a reasonable expectation of success in preparing a tetracycline loaded manganese-based organic framework taught by the combination of Sun, Wen, and Zhou.
As described above, Sun teaches that the Mn2(TCPE)(H2O)(DMF) MOF has channels of a size of 4.7 x 7.8 Å2 (pg. 6107, left column, first paragraph). Additionally, to the extent that such a change is predictable, for the reasons set forth above, in view of Wen and Zhou, it would be expected that the modified version of the MOF of Sun, modified by the methods taught by Wen and Zhou to achieve the Mn2(TCPE)(H2O) MOF, would have a smaller channel size in the MOF. Taherzade teaches loading tetracycline into a MIL-100 MOF containing a pore size of 1.7 or 1.2 nm, as tetracycline has a molecular size of 1.1 nm (pg. 2, paragraph 4). To the examiner’s understanding, in the field of MOFs, the terms pore and channel describe the same structural feature of the MOF and can be used interchangeably. Thus, in view of these teachings, the skilled artisan would not predict that tetracycline could effectively be loaded into the MOF of the combination of Sun, Wen, and Zhou, as the predicted channel size is too small to accommodate the tetracycline molecule. In addition to the pore size difference, the material makeup of the MIL-100 MOF of Taherzade differs from the instantly claimed manganese and TCPE MOF.
Additionally, none of the above cited references teach TCPE fluorescence and pH-responsive tetracycline release properties of a manganese and TCPE containing MOF system.
Response to Arguments
Applicant’s arguments, filed July 30, 2026, with respect to the claim rejections based on prior art, have been fully considered and are persuasive. The rejections of the pending claims under 35 U.S.C. 103 has been withdrawn. As described above, the prior art does not teach loading a Mn2(TCPE)(H2O) MOF with tetracycline.
Applicant’s arguments, filed July 30, 2026, with respect to the claim rejections under 35 U.S.C. 112, have been fully considered but they are not persuasive.
Applicant asserts that claims 2, 3, 9, and 19 have been amended to correct various features of the claims and claim language.
However, this is not persuasive. Regarding claims 3, 9, and 19, the same indefiniteness issue present before persists in the amended claims. In claim 3, the nanoparticles and aggregates are not clearly set forth or described. In claim 9, the values to calculate the claimed ratios is not specified. In claim 19, it is not clear what motion the constant speed refers to. Additionally, the amendment to claim 2 has not sufficiently resolved the conflict between the claimed size range and the amended claim language (see rejection above).
Conclusion
Claims 1, 6-8, 10-18, and 22-23 are allowed.
Claims 2, 3, 9, 19, and 21 are rejected.
Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric P Mosher whose telephone number is (571)272-3258. The examiner can normally be reached Monday-Friday 9am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/E.P.M./ Examiner, Art Unit 1612
/SAHANA S KAUP/ Supervisory Primary Examiner, Art Unit 1612